US Allows Increased Production Of Takeda’s ADHD Drug to Address Shortage

(Reuters) – The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States.
The raised production limit follows the Food and Drug Administration’s request in July, the DEA said in a notice on Tuesday.
Attention deficit hyperactivity disorder (ADHD) drugs have been in short supply for years. The FDA warned of a shortage of Israel-based drugmaker Teva Pharmaceutical Industries’ Adderall in October 2022, troubled by manufacturing delays.
That led to a spike in demand and subsequent shortage of Takeda’s Vyvanse.
Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and additional prescribing safeguards are put in place.
The production limit for lisdexamfetamine was increased by 6,236 kilograms (kg), which includes 1,558 kg to address increased domestic demand and 4,678 kg for increased foreign demand for finished dosage medications, according to the DEA.
“These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally,” DEA said.
US FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical Industries, last year after Takeda lost exclusivity over the drug.
Bloomberg News first reported about the increased limits on Tuesday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore)
 
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.